Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2023 Aug:151:208934.
doi: 10.1016/j.josat.2022.208934. Epub 2023 Jan 6.

Methamphetamine use and illicit opioid use during buprenorphine treatment

Zoë Kratina-Hathaway  1 , Andrea C Radick  2 , Brian G Leroux  3 , Kendra Blalock  4 , Theresa W Kim  5 , James Darnton  2 , Andrew J Saxon  6 , Jeffrey H Samet  5 , Judith I Tsui  2
Affiliations
Randomized Controlled Trial

Methamphetamine use and illicit opioid use during buprenorphine treatment

Zoë Kratina-Hathaway et al. J Subst Use Addict Treat. 2023 Aug.

Abstract

Introduction: Although methamphetamine use is rising in the United States, its impacts on patient outcomes among persons undergoing treatment for opioid use disorder (OUD) remain unclear. This study aims to assess the association between baseline methamphetamine/amphetamine (MA/A) use and subsequent illicit opioid use among patients with OUD initiating buprenorphine in an office-based setting.

Methods: We conducted a secondary analysis of a pilot randomized controlled trial of a behavioral mobile health intervention for buprenorphine adherence conducted over a 12-week study period at two clinic sites. The study defined baseline MA/A use by a positive urine drug test (UDT) and/or self-report of use within the past 30-days. Separate Poisson regression models with robust standard errors evaluated associations between MA/A and: i) illicit opioid use measured by weekly UDT (primary) and ii) self-reported past 30-day use at end of study (secondary). Other secondary outcomes included buprenorphine positive UDTs throughout the study and retention in OUD treatment at both weeks 12 and 24 post-randomization.

Results: At baseline, 28 (36%) of the 78 participants had MA/A use and use was associated with a statistically significant increase in risk of testing positive for illicit opioids on UDT during the study follow-up period (adjusted relative risk (aRR)=1.54; 95% CI=1.09-2.17; p=0.015), as well as an increased risk for reported past 30-day illicit opioid use at week 12 (aRR=3.86; 95% CI=1.47-10.18; P=0.006). The study found no significant associations between MA/A use and buprenorphine positive UDT or retention in OUD treatment.

Conclusions: In this sample of patients initiating buprenorphine, methamphetamine/amphetamine use at baseline was associated with illicit opioid use over a 12-week period. These findings demonstrate how co-use of methamphetamine can impede attainment of ideal OUD treatment outcomes.

Keywords: Buprenorphine; Directly observed therapy; Medication adherence; Methamphetamine use; Opioid related disorders.

PubMed Disclaimer

Conflict of interest statement

Competing Interests: None

Figures

Fig. 1.
Fig. 1.
Weekly percentage of opioid positive UDTs by Methamphetamine/Amphetamine group. Number of weekly opioid positive UDTs shown in table.
See this image and copyright information in PMC

References

    1. Al-Tayyib A, Koester S, Langegger S, & Raville L. (2017). Heroin and Methamphetamine Injection: An Emerging Drug Use Pattern. Substance Use and Misuse, 52(8), 1051–1058. 10.1080/10826084.2016.1271432 - DOI - PMC - PubMed
    1. Alford DP, LaBelle CT, Kretsch N, Bergeron A, Winter M, Botticelli M, & Samet JH (2011). Collaborative care of opioid-addicted patients in primary care using buprenorphine: five-year experience. Archives of Internal Medicine, 171(5), 425–431. 10.1001/archinternmed.2010.541 - DOI - PMC - PubMed
    1. Baker R, Leichtling G, Hildebran C, Pinela C, Waddell EN, Sidlow C, . . . Korthuis PT (2021). “Like Yin and Yang”: Perceptions of Methamphetamine Benefits and Consequences Among People Who Use Opioids in Rural Communities. J Addict Med, 15(1), 34–39. 10.1097/ADM.0000000000000669 - DOI - PMC - PubMed
    1. Becker WC, & Fiellin DA (2020). When Epidemics Collide: Coronavirus Disease 2019 (COVID-19) and the Opioid Crisis. Annals of Internal Medicine, 173(1), 59–60. 10.7326/M20-1210 - DOI - PMC - PubMed
    1. Cai Y, Dai Z, Wen S, & Bhandari R. (2020). Risk factors associated with infection of blood-borne virus among people who used methamphetamine. BMC Infectious Diseases, 20(1), 742. 10.1186/s12879-020-05464-y - DOI - PMC - PubMed

Publication types

MeSH terms